Clinical trials: QTc Interval
Advanced Solid Tumors
A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors
The purpose of this study is to obtain QTc data, to assess the effects of tivozanib on ECG morphology, and to determine the pharmacokinetic pharmacodynamic (PK-PD) relationship between any observed changes in cardiac…
- Trial name
- NCT01210846
- Testing
- tivozanib
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Basic Science
A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants
The primary objective of the study is: To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in…
- Trial name
- NCT06411860
- Testing
- Olpasiran, Moxifloxacin
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)
Researchers are looking for new treatments for HIV-1 (human immunodeficiency virus type 1) that are safe, well-tolerated, and can be taken less often.
- Trial name
- NCT07305831
- Testing
- Ulonivirine, Moxifloxacin
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Autoimmune Diseases
A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects
This study will investigate the effects of therapeutic and supratherapeutic oral doses of CBP-307 on the QTc interval in healthy subjects.
- Trial name
- NCT04818229
- Testing
- CBP-307, Moxifloxacin (Avelox)
- Where
- 2 sites in United States, Australia
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Connect Biopharma Australia Pty Ltd
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
The purpose of this study is to 1) determine whether the effect on QT interval corrected (QTcLD) for heart rate using the population specified linear derived method at steady state is comparable between 12 mg paliperidone…
- Trial name
- NCT00791622
- Testing
- Paliperidone ER
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Volunteers
A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics
A randomized, single-center, placebo and positive control, 4-period and 4-crossover clinical study with the following main purposes: (1) To evaluate the effect of a single-dose oral administration of nemonoxacin malate capsule on…
- Trial name
- NCT03362853
- Testing
- Nemonoxacin 500Mg Capsule, Moxifloxacin 400Mg Tablet, Nemonoxacin 750Mg Capsule
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- TaiGen Biotechnology Co., Ltd.
Infection, Human Immunodeficiency Virus
Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction
This study is being conducted to comply with the Food and Drug Administration (FDA) recommendation that all new non anti-arrhythmic drugs be assessed for cardiac repolarization effects through electrocardiographic evaluation.
- Trial name
- NCT02027454
- Testing
- GSK1265744, Moxifloxacin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
QTc Interval
Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose
The purpose of this study is define the electrocardiographic (ECG) effects of Droxidopa at clinical (600 mg) and supratherapeutic (2000 mg) doses compared with placebo and moxifloxacin in healthy male and female subjects.
- Trial name
- NCT01327066
- Testing
- Droxidopa, Moxifloxacin
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Chelsea Therapeutics
Cancer, Solid Tumor
Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes
The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.
- Trial name
- NCT01017731
- Testing
- IMC-1121B, Moxifloxacin, Diphenhydramine
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Diabetes
Effect of Glucose on QTc Interval in Type 1 Diabetes
High blood glucose levels (hyperglycaemia) and Moxifloxacin (a commonly used antibiotic) have both been shown independently to affect heart activity in healthy volunteers as recorded by ECG. i.e.
- Trial name
- NCT01984827
- Testing
- Moxifloxacin, hyper-glycaemic clamp
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Richmond Research Institute
Human Experimentation (Human Volunteers)
Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers
This phase I trial will evaluate the effects of rupatadine, at a dose of 10 mg OD (authorised and marketed dose) and the 100mg/day (supratherapeutic dose) on the ECG parameters with a special focus on its effect on cardiac…
- Trial name
- NCT00199225
- Testing
- Rupatadine, moxifloxacin, Continous electrocardiographic register
- Where
- Spain
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- J. Uriach and Company
Opioid Dependence, Methadone Withdrawal Syndrome
Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients
The primary objective of this study is to assess QTc (an interval of the heart rhythm) interaction effects between lofexidine and methadone.
- Trial name
- NCT01650649
- Testing
- Lofexidine HCl, Lofexidine-matching sugar pill
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Healthy Volunteers, Healthy
A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers
This is a partially double-blind study in healthy adult subjects, which will be conducted as a placebo- and active-controlled, single-dose, crossover study.
- Trial name
- NCT03164109
- Testing
- GC4419 IV, Oral moxifloxacin
- Where
- Australia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Cancer
A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
The primary objective of this study is to evaluate the effects of aflibercept on the QTc interval in cancer patients. Secondary objectives are to evaluate the effects of aflibercept on other electrocardiogram (ECG) parameters…
- Trial name
- QUTIE (NCT00876044)
- Testing
- aflibercept (AVE0005)
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 88 people
- Sponsor
- Sanofi
Healthy
A Study of LY3039478 in Healthy Participants
The main purpose of this study is to investigate the safety of the study drug known as LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part A has three periods.
- Trial name
- NCT02659865
- Testing
- LY3039478 Capsule Formulation (Formulation 3), LY3039478 Drug-in Capsule (Reference, Formulation 1), LY3039478 Formulated Capsule (Test, Formulation 3)
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hypertension, Mineralocorticoid Receptor Antagonist
The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers
This study will test if a study drug (CS-3150) will affect the heart rate in healthy males and females. Two doses of the study drug will be tested. Heart rate is not expected to be different between the study groups.
- Trial name
- NCT04019652
- Testing
- CS-3150, Moxifloxacin
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Healthy
A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on the heart rate-corrected QT (QTc) interval and to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and…
- Trial name
- NCT06215521
- Testing
- Pirtobrutinib, Moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Ventricular Repolarization
A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects
This study is conducted to evaluate the effectiveness of DIC075V on ventricular repolarization in healthy subjects compared to placebo after a single dose of DIC075V administered intravenously (IV) and to evaluate ECG assay…
- Trial name
- NCT01812538
- Testing
- DIC075V
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Healthy
A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function
Two-part Phase 1 study to assess the effect of single therapeutic and supra-therapeutic doses of lucerastat on the QT/QTc interval duration in healthy subjects (Part A: Pilot study; Part B: TQT study)
- Trial name
- NCT03832452
- Testing
- Lucerastat (Treatment A), Moxifloxacin, Lucerastat (Treatment B)
- Where
- Netherlands
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy
The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects
Evaluate the effect of multiple doses (once daily for 3 days each of HYD 80, 120, and 160 mg tablets) on the QT/QTc interval.
- Trial name
- NCT02243241
- Testing
- HYD, Moxifloxacin
- Where
- United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Purdue Pharma LP